OriGene Establishes High Throughput Monoclonal Antibody Production Outsourcing Center in China
News Feb 13, 2009
OriGene Technologies, Inc. has announced it has raised an additional $6.5 million in a private equity financing. With this financing, OriGene completed the acquisition of the assets of privately held Shenzhen P&A Biotech, a manufacturer and provider of monoclonal antibodies (mAb) to the research community.
With this acquisition OriGene completes the establishment of its technology center to develop genome-wide monoclonal antibodies to all human proteins.
Over the last ten years OriGene has developed the capacity to produce thousands of human full-length proteins from human cells. These human cell produced human proteins are ideal antigens for high throughput monoclonal antibody production. During the last two years, OriGene also has developed a genome wide collection of antigen standards and over 100,000 tissue samples that are ideal tools for high quality antibody validation.
With OriGene's China monoclonal antibody production capacity and these genome-wide resources OriGene believes it can produce several thousand high quality monoclonal antibodies per year.
This genome-wide mAb production capacity is available to all commercial and academic partners with a long-term goal to providing high quality monoclonal antibodies for every single human gene.